The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.
August 28th 2025
Biosimilars can be a more affordable and accessible treatment option for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
Evolving Business Models in Specialty and Infusion Pharmacy
July 29th 2025Hospitals and health systems are adapting specialty and infusion pharmacy strategies to meet evolving payer mandates, rising costs, and shifting care models by expanding biosimilar use, optimizing prior authorizations, and integrating technology to enhance patient access and operational efficiency.
Read More
ATOPP 2025: Navigating Biosimilar Adoption and Operational Strategies in Oncology
July 14th 2025Laura R. Bobolts, PharmD, BCOP, shares actionable strategies for oncology pharmacists to navigate biosimilar and 505(b)(2) drug implementation, manage payer and formulary complexities, and optimize cost-effective care delivery across oncology service lines.
Read More
ATOPP 2025: Pharmacy Innovation at the Intersection of EOM and Patient Access
July 10th 2025Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses how oncology pharmacists can lead value-based care efforts under the Enhanced Oncology Model (EOM) by improving care coordination, managing costs, aligning with performance metrics, and leveraging clinical data systems to enhance patient outcomes.
Read More